Browse Technologies
Browse Technologies
Technology Keyword Search
Search Results
Displaying: 51 - 60 of 270 Results
Modulating the Blood-Brain Barrier (BBB) to enable delivery of drugs and development of therapeutics
The blood–brain barrier (BBB) helps maintain a constant, optimal environment for neuronal function through a combination of barriers and selective transport systems that regulate the passage of wanted and unwanted molecules. While important for…
DBD
- Irit Ben-Chelouche
Investigators
- Chenghua Gu
Anti-cancer Therapeutic Strategy Targeting Ammonium Metabolism
Cancer has long been recognized as a disease of altered cellular metabolism as cancer cells have an abnormally high demand for nutrients to support their growth and proliferation. However, targeting cancer cell metabolism has not been seriously…
DBD
- Irit Ben-Chelouche
Investigators
- Marcia Haigis
- Jessica Spinelli
aP2 knock-out mice
AP2 knock-out mutant mice were developed by Dr. Gokhan Hotamisligil at Harvard Medical School (Science. 1996 Nov 22;274(5291):1377-9). AP2, also known as Fatty Acid-Binding Protein 4 (FABP4), encodes the adipocyte FABP. It plays important roles in…
DBD
- Vivian Berlin
Investigators
- Gokhan Hotamisligil
Polycystic Kidney Disease: Mechanistic Dissection and Discovering Precision Therapeutic Targets
Autosomal-dominant polycystic kidney disease (ADPKD) is a life-threatening monogenic disease that affects nearly 1 million people in the U.S. alone. ADPKD represents a very large unmet medical need, currently without remedy. It is characterized by…
DBD
- Grant Zimmermann
Investigators
- Adrian Salic
KRT14-Cre mouse line
Hemizygous Tg(KRT14-cre)1Amc/J (also known as K14-Cre) transgenic mice were developed in the laboratory of Dr. Andrew P. McMahon at Harvard University. The mouse strain harbors Cre recombinase under the control of human keratin-14 promoter, which…
DBD
- Vivian Berlin
Investigators
- Andrew McMahon
Ngn3-Cre transgenic mice for studying pancreatic development
Hemizygous transgenic Tg(Neurog3-cre/Esr1*)1Dam/J mice (also known as Ngn3/CreERTM) were developed in the laboratory of Dr. Douglas A. Melton at Harvard University. The mice contain a fusion protein of Cre recombinase and mutant mouse estrogen…
DBD
- Vivian Berlin
Investigators
- Douglas Melton
Glp1r-ires-Cre (Glp1r-ires-Cre knock-in mice)
Glp1r (Glucagon-Like Peptide 1 Receptor) -ires-Cre knock-in mice were developed in Dr. Stephen Liberles lab at Harvard Medical School. IRES and Cre sequence were inserted after the gene Glp1r, thus the mouse strain expresses Cre recombinase in cells…
DBD
- Grant Zimmermann
Investigators
- Stephen Liberles
Gpr65-ires-Cre (Gpr65-ires-Cre knock-in mice)
Gpr65 (G Protein-Coupled Receptor 65) -ires-Cre knock-in mice were developed by Dr. Stephen Liberles and members of his lab at Harvard Medical School. In these mice, expression of Cre recombinase is controlled by Gpr65 promoter in Gpr65-positive…
DBD
- Grant Zimmermann
Investigators
- Stephen Liberles
Hba-a1 knockout mice
Homozygous Hba-a1 (hemoglobin alpha, adult chain 1) knockout mice (129S-Hba-a1tm1Led/J) were developed by HHMI Investigator Dr. Philip Leder and his lab at Harvard Medical School. While the mice are viable and fertile, they develop anemia with…
DBD
- Irit Ben-Chelouche
Investigators
- Philip Leder
CD1- mice developed in the laboratory of Dr. Michael Grusby
Homozygous Cd1tm1Gru knock-out mice (C.129S2-Cd1tm1Gru/J, also known as CD1-) were developed by Dr. Michael J. Grusby at Harvard University. The mutant mice are deficient in both the Cd1.1 and Cd1.2 genes, and lack the normal natural killer…
DBD
- Grant Zimmermann
Investigators
- Michael Grusby